TY  - JOUR
A1  - Del Galdo, Francesco
A1  - Lescoat, Alain
A1  - Conaghan, Philip G
A1  - Bertoldo, Eugenia
A1  - ?oli?, Jelena
A1  - Santiago, Tânia
A1  - Suliman, Yossra A
A1  - Matucci-Cerinic, Marco
A1  - Gabrielli, Armando
A1  - Distler, Oliver
A1  - Hoffmann-Vold, Anna-Maria
A1  - Castellví, Ivan
A1  - Balbir-Gurman, Alexandra
A1  - Vonk, Madelon
A1  - Ananyeva, Lidia
A1  - Rednic, Simona
A1  - Tarasova, Anna
A1  - Ostojic, Pedrag
A1  - Boyadzhieva, Vladimira
A1  - El Aoufy, Khadija
A1  - Farrington, Sue
A1  - Galetti, Ilaria
A1  - Denton, Christopher P
A1  - Kowal-Bielecka, Otylia
A1  - Mueller-Ladner, Ulf
A1  - Allanore, Yannick
KW  - Connective Tissue Diseases
KW  -  Pulmonary Arterial Hypertension
KW  -  Pulmonary Fibrosis
KW  -  Scleroderma
KW  -  Systemic
KW  -  Therapeutics
JF  - Annals of the Rheumatic Diseases
UR  - https://doi.org/10.1136/ard-2024-226430
PB  - BMJ
N2  - OBJECTIVES: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. METHODS: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review. The evidence derived was discussed and overarching principles, recommendations and future research agenda were iteratively developed with voting rounds. RESULTS: The task force agreed on 22 recommendations covering 8 clinical/organ domains including Raynaud's phenomenon, digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis, skin fibrosis, interstitial lung disease (ILD), gastrointestinal manifestations and arthritis. Most new recommendations are related to skin fibrosis and ILD. These included novel recommendations for the use of mycophenolate mofetil, nintedanib, rituximab and tocilizumab for the treatment of these crucial disease manifestations. The recommendations also included first-line and second-line interventions, providing increased utility for rheumatology practitioners. Important additions to the future research agenda included consideration of novel interventions for the management of vascular, musculoskeletal and gastrointestinal manifestations and calcinosis, as well as for the local management of digital ulcers. CONCLUSION: These updated recommendations include the first set of synthetic and biological targeted therapies recommended for key fibrotic manifestations of SSc as well as first-line combination treatment for newly diagnosed pulmonary artery hypertension and prioritise a new research agenda for the coming years.
ID  - discovery10198752
N1  - © 2024 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
VL  - 84
AV  - public
SP  - 29
Y1  - 2025/01//
EP  - 40
TI  - EULAR recommendations for the treatment of systemic sclerosis: 2023 update
ER  -